Vigil Neuroscience announced a peer-reviewed research publication that reported new data on the prevalence and clinical significance of CSF1R gene variants in the UK population. The research, published in the journal Neurology Genetics and conducted by Wade et al., suggests the estimated prevalence of adult-onset leukoencephalopathy with axonal-spheroids and pigmented glia is underreported in the U.S., EU, and UK.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer’s Association International Conference (AAIC)
- Vigil Neuroscience’s Promising Phase 1 Trial and Alzheimer’s Focus
- Vigil Neuroscience announces interim data from ongoing Phase 1 trial on VG-3927
- Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
- Vigil Neuroscience price target lowered to $17 from $24 at H.C. Wainwright